Cocaine-assisted epithelial debridement for the treatment of anterior basement membrane dystrophy.

PURPOSE: To describe a method of epithelial debridement with the adjunctive use of topical cocaine for the treatment of symptomatic anterior basement membrane dystrophy (ABMD). METHODS: Retrospective consecutive chart review. Symptomatic patients with ABMD were treated with 4% topical cocaine followed by epithelial debridement. Preoperative and postoperative best-corrected visual acuities (BCVA), topography, subjective symptoms, complications, and evidence of disease recurrence were recorded. RESULTS: Thirty-three eyes of 27 patients were included. The average follow-up duration was 5 years (range, 1.3 months to 8 years). Fourteen patients (17 eyes) presented with recurrent erosion symptoms (group 1) and 13 patients (16 eyes) presented with reduced visual acuity from irregular astigmatism (group 2). Only 1 patient from group 1 experienced symptomatic recurrence of the corneal erosion. In this group, BCVA improved from a mean of 20/45 preoperatively to 20/38 at the last follow-up visit. In group 2, BCVA improved from a mean of 20/63 preoperatively to 20/32 at the last follow-up visit. No major recurrences were noted at the last follow-up visit in this group. No residual effect from the application of cocaine was noted in any of the eyes. Significant postoperative corneal haze occurred in 1 eye. CONCLUSIONS: Topical cocaine-assisted epithelial debridement offers a simple and inexpensive method for treating patients with ABMD who experience recurrent corneal erosions and/or irregular astigmatism resulting in decreased visual acuity.

Indications, visual outcome, and ectasia in clear corneal transplants 20 years old or more.

PURPOSE: To report the indications, visual outcome, and development of ectasia in clear corneal transplants at least 20 years or more after penetrating keratoplasty (PK). METHODS: A computer search of all post-PK patients in the electronic medical records of the Cornea Service was done. Only patients with clear primary grafts aged 20 years or more were included. Main outcome measures noted were indications for surgery, final visual outcome, and postoperative complications. A subset of patients who developed ectasia clinically was also analyzed. RESULTS: One hundred forty-nine eyes of 109 patients were identified. The most common indication was keratoconus (76.5%). After average follow-up of 27 years, the mean postoperative best-corrected visual acuity was 0.29 ± 0.38 logarithm of the minimum angle of resolution (Snellen equivalent 20/39). Postoperative complications included rejection (29.5%), cataract formation (26.2%), and steroid-induced elevated intraocular pressure (15.4%). Peripheral thinning and ectasia diagnosed by slit lamp were noted in 59 eyes (39.6%), most of which were mild (54.2%), inferiorly located (66.1%), and involved the graft-host junction (81.4%). Most of the grafts that developed ectasia had a preoperative diagnosis of keratoconus (91.5%). Mean postoperative visual acuity of ectatic grafts with rigid gas permeable contact lens and/or glasses was 0.24 ± 0.25 logarithm of the minimum angle of resolution (Snellen equivalent 20/34). CONCLUSION: PK grafts can remain clear for 20 years or more and have excellent visual outcome. Most of the 20-year-old grafts in our study were in patients with keratoconus. Rejection and graft-host ectasia are problems to be encountered in long-surviving grafts. Ectatic grafts can still attain good vision with properly fitted contact lenses and glasses.

Dry eye syndrome in aromatase inhibitor users.

BACKGROUND: Aromatase inhibitors are frequently used as an adjuvant therapy in the treatment of breast cancer. We observed that several patients taking aromatase inhibitors presented with severe dry eye symptoms, and we investigated whether there is a relationship between aromatase inhibitors and dry eyes in these patients. DESIGN: Retrospective chart review. PARTICIPANTS: Forty-one women. METHODS: A computerized search of health records was performed to identify patients using anastrazole, letrozole and exemestane seen by the Cornea Service from August 2008 to March 2011. The results were compared with age-matched controls. MAIN OUTCOME MEASURES: Ocular surface changes among aromatase inhibitors users. RESULTS: Of the 41 women, 39 were Caucasians. Thirty-nine patients had breast cancer (95%), one patient had ovarian cancer (2.5%) and one had an unknown primary cancer. Mean age was 68 ± 11.3 years (range 47-95). Most common presenting symptoms were blurred vision in 28 (68%) patients, irritation/foreign body sensation in 12 (29%) patients, redness in 9 (22%) patients, tearing in 6 (22%) patients and photosensitivity in 2 (5%) patients. Mean Schirmer's test measurement was 11 ± 5.8 mm (range 0.5-20 mm). Blepharitis was noted in 68 of 82 eyes (73%), decreased or poor tear function in 24 eyes (29%), conjunctival injection in 18 eyes (22%) and superficial punctate keratitis in 12 eyes (29%). Among an age-matched population (45-95 years), dry eye syndrome was found in only 9.5% of patients. CONCLUSIONS: Because the prevalence of ocular surface disease signs and symptoms appears to be higher in study group than control patients, aromatase inhibitors might be a contributing factor to the dry eye symptoms.

Treatment of mucous membrane pemphigoid with mycophenolate mofetil.

PURPOSE: To evaluate the clinical outcomes of mycophenolate mofetil (MMF) treatment of mucous membrane pemphigoid (MMP). METHODS: This is a retrospective analysis of consecutive patients with clinical MMP seen in the Ocular Surface Disease Clinic at the Wills Eye Institute, between January 1, 2004, and December 31, 2010, treated with MMF. The main outcomes measured were control of inflammation and discontinuation of MMF. RESULTS: A total of 23 MMP patients taking MMF were identified. The median age of the MMF-treated patients was 77.0 years. Eleven of the 23 patients (47.8%) had biopsy-proven MMP. All patients were at least Foster grading system stage 2, with most stage 3 or 4. Eight patients (34.8%) failed previous treatments with dapsone, methotrexate, prednisone, azathioprine, cyclophosphamide, or 6-mercaptopurine. The average duration of MMF treatment was 23.32 ± 33.17 months (range 1-124.83 months, median 7.4 months). Of the 23 patients with MMP, control of inflammation was achieved with MMF within 3 months for 56.5% [95% confidence interval (CI) 54.5-59.6], within 6 months for 69.6% (95% CI 65.2-76.6), and within 12 months for 82.6% (95% CI 75.3-92.4) of the patients. Nineteen patients (82.4%) achieved control of inflammation, with 16 of the 19 (84.2%) achieving control of inflammation with MMF as monotherapy. Fifteen patients were treated with MMF as initial therapy. Twenty-one percent of patients (5 of 23) were taken off MMF for failure of inflammatory control (4) or an allergic reaction (1). CONCLUSIONS: Treatment of MMP with MMF in this uncontrolled case series resulted in control of inflammation in the majority of patients with minimal side effects. Our data support consideration of MMF as an initial treatment option for active ocular MMP.

Descemet membrane detachment among siblings: role of anatomic and familial predisposition.

PURPOSE: To describe 2 siblings with Descemet membrane detachment (DMD) after intraocular surgery and discuss the potential role of anatomic and familial predisposition. METHOD: Case reports. RESULTS: A 64-year-old woman had bilateral DMDs after trabeculectomy in her right eye and during combined cataract extraction and trabeculectomy in her left eye. Both were successfully treated with intracameral sulfur hexafluoride gas injections. Her older sister also developed DMD in her left eye that was noted after uncomplicated cataract surgery. Slit-lamp examination of her unoperated eye revealed irregular Descemet membrane with thickening and a wavy configuration, suggesting an intrinsic corneal abnormality. No endothelial guttae or polymorphous changes were noted. Intracameral sulfur hexafluoride gas injection was attempted to reattach the Descemet membrane but was unsuccessful. The patient then underwent Descemet stripping endothelial keratoplasty with excellent postoperative results. CONCLUSIONS: Predisposition to DMD among relatives may be linked to hereditary morphological abnormalities present in their corneas.

Endothelial keratoplasty without Descemet's stripping in eyes with previous penetrating corneal transplants.

AIMS: To evaluate techniques, outcomes and complications of endothelial keratoplasty (EK) without Descemet's stripping in eyes with previous penetrating keratoplasty (PK). METHODS: A retrospective, consecutive analysis of patients who underwent EK in eyes with previous PK. RESULTS: 33 eyes of 31 consecutive patients underwent EK without Descemet's stripping in eyes with previous PK. All 33 eyes were followed for an average of 14.2 ± 4.4 months. The reason for EK was either graft rejection (n=9) or endothelial failure (n=24). 32/33 (97.0%) eyes remained clear at the last follow-up visit. Visual acuity improved in 28/33 (84.8%) patients with 19/28 (67.9%) of these patients having more than three lines of visual acuity improvement. The average postoperative vision in this group was 20/60 (range 20/25-20/100). Pre-cut donor tissue was used for all cases with an average thickness of 127 µm. Endothelial cell density declined by 35% at 3 months and was stable at 1 year. 2/33 (6%) eyes had graft dislocations. One eye was successfully treated by a re-bubble. The other case failed EK revision and required a repeat PK. No patients developed EK or PK graft failure/rejection. CONCLUSION: EK without Descemet's membrane stripping in eyes with previous PK graft failure/rejection is a valuable alternative to a repeat full thickness PK.